Johns Hopkins University

BREAKTHROUGH ACTION

INTERNATIONAL MATERNAL PEDIATRIC ADOLESCENT AIDS CLINICAL TRIALS (IMPAACT) GROUP

NATIONAL STUDY OF DISABILITY TRENDS AND DYNAMICS

ECHODAC (ENVIRONMENTAL INFLUENCES ON CHILD HEALTH OUTCOMES DATA ANALYSIS CENTER)

REGIONAL ONCOLOGY RESEARCH CENTER

HEALTHCOMM CAPACITY

HIV PREVENTION TRIALS NETWORK: NETWORK LABORATORY

STRENGTHENING SAFE HOSPITALS AND CLINICS IN HIV/AIDS PREVENTION ACTIVITIES, SERVI

A COLLABORATIVE PROGRAM FOR THE MULTISCALE MODELING AND DESIGN OF MATERIALS FOR EXTREME DYNAMIC ENVIRONMENTS

ENHANCING GLOBAL HEALTH SECURITY: EXPANDING EFFORTS AND STRATEGIES TO PROTECT AND IMPROVE PUBLIC HEALTH GLOBALLY

TECHNICAL SUPPORT IN HIV TREATMENT, CARE AND PREVENTION IN ETHIOPIA

PROVIDE SUPPORT TO TREATMENT PROGRAM

THE JOHNS HOPKINS CENTER FOR AIDS RESEARCH (JHU CFAR)

NORTH AMERICAN AIDS COHORTS COLLABORATION ON RESEARCH AND DESIGN

NEW HORIZONS IN THE PREVENTION AND TREATMENT OF FOOD ALLERGY

INSTITUTE FOR CLINICAL AND TRANSLATIONAL RESEARCH (UL1)

INSTITUTE FOR CLINICAL AND TRANSLATIONAL RESEARCH

THE PROJECT WILL DEVELOP EFFECTIVE NEW TOOLS AND APPROACHES TO FIND, TREAT AND PREVENT TB, AS WELL AS TESTING NOVEL STRATEGIES FOR IMPLEMENTING THE DELIVERY OF NEW DRUGS AND DIAGNOSTIC PRODUCTS IN REAL-WORLD, LOW RESOURCE SETTINGS.

PREVENTION OF MALARIA THROUGH VECTOR CONTROL

DATA DISPARITIES SUPPLEMENT TO JOHNS HOPKINS INSTITUTE FOR CLINICAL AND TRANSLATIONAL RESEARCH

MATERIALS SCIENCE IN EXTREME ENVIRONMENTS

NEUROTECH HARBOR: OUR NATION'S FIRST EQUITECH ECOSYSTEM FOR NEUROMEDICAL TECHNOLOGIES - PROJECT SUMMARY OVERALL THE TWO AIMS OF NEUROTECH HARBOR ARE: (AIM 1) TO ACCELERATE EARLY DEVELOPMENT OF THE MOST PROMISING NEUROMEDICAL SOLUTIONS, AND (AIM 2) TO INCREASE THE NUMBER OF WOMEN & URM INNOVATORS THROUGH OUTREACH AND EDUCATION, AND TO IMPROVE EQUITY AND ACCESSIBILITY OF NEUROMEDICAL SOLUTIONS. NEUROTECH HARBOR (NTH), LED BY JOHNS HOPKINS AND HOWARD UNIVERSITIES, WILL ACCELERATE THE DEVELOPMENT OF HIGHLY PROMISING SOLUTIONS TO IMPROVE NEUROLOGICAL HEALTH FOR ALL. SOLUTIONS FOR ALL MEANS ALSO FOR THE UNDERSERVED, OFTEN SYNONYMOUS WITH MINORITY GROUPS. DIVERSE INNOVATORS SHOULD SIT AT THE TABLE ON DAY ONE, BUT VERY FEW MINORITY ENTREPRENEURS EXIST. TO ADDRESS THESE INEQUITIES, WE WILL BUILD NTH WITH AN EQUITECH PHILOSOPHY, WHICH IS THE BELIEF THAT DIVERSITY OF TEAMS, LEADERSHIP, AND PERSPECTIVES IS A FORCE MULTIPLIER TO FUEL INNOVATION, PRODUCING SOLUTIONS ACCESSIBLE TO ALL COMMUNITIES. HOPKINS & HOWARD ARE UNIQUELY POSITIONED TO REALIZE THIS VISION. HOPKINS BRINGS A FOUNDATION OF RESEARCHERS, PRESTIGIOUS RESEARCH CENTERS, AND PROGRAMS AND HAS A TRANSLATION TRACK RECORD ($3B INVESTED IN START-UPS IN THE LAST 7 YEARS). HOWARD COMPLEMENTS THIS WITH A LARGE PIPELINE OF ASPIRING UNDER-REPRESENTED MINORITY (URM) INNOVATORS BOTH WITHIN AND OUTSIDE THE HOWARD COMMUNITY. HOWARD HAS NURTURED THIS COMMUNITY WITH EARLY-STAGE MENTORSHIP, A SUCCESSFUL INCUBATOR PROGRAM, AND RECENTLY RECEIVED A $17M GRANT TO CREATE A CENTER FOR ENTREPRENEURSHIP AIMED AT BUILDING RESOURCES AND SUPPORT FOR BLACK BUSINESS OWNERS ACROSS THE COUNTRY. NTH WILL SOLICIT PROPOSALS FROM INNOVATORS NATIONWIDE ADDRESSING PRESSING PROBLEMS. ALTHOUGH THE AREAS SUPPORTED WILL BE BROAD, COVERING ALL PARTICIPATING NIH INSTITUTES AND CENTERS, THE EXPERTISE OF NTH WILL BE INCLUSIVE BUT FOCUSING ON NEUROPROSTHESIS (CORTICAL, SPINAL, PERIPHERAL, VISION, AND AUDITORY), BRAIN MACHINE INTERFACE, NEURO SENSORS AND DEVICES, NEURO INFORMATICS, NEUROMODULATION, AND MENTAL HEALTH. FOR FUNDED PROJECTS, RESOURCES WILL BE PROVIDED, AND A DREAM TEAM OF SPECIALISTS WILL OFFER MENTORSHIP AND TOOLS TO GUIDE SUCCESSFUL TRANSLATION TO FIRST-IN-HUMAN PROTOTYPE. SPECIALISTS WILL BE DRAWN FROM A DIVERSE STEERING COMMITTEE, ADVISORY BOARD, AND CONSULTANT NETWORK, COMPOSED OF HIGHLY REGARDED CLINICIANS, SCIENTISTS, TECHNOLOGISTS, COMMERCIALIZATION EXPERTS, AND PATIENT ADVOCATES. TO EXPAND DIVERSITY AMONGST INNOVATORS, NTH HAS FORMED STRATEGIC OUTREACH PARTNERSHIPS WITH ACCESS TO HISTORICALLY BLACK COLLEGES AND UNIVERSITIES AND MINORITY SERVING INSTITUTIONS ACROSS THE NATION. WE HAVE CREATED AN NTH INSTITUTE, A CENTER FOR INNOVATOR LEADERSHIP DEVELOPMENT TO EDUCATE INNOVATORS IN BUSINESS DEVELOPMENT, TRANSLATION AND PROJECT MANAGEMENT. IMPORTANTLY, OUR NEEDS ASSESSMENTS WILL BE GUIDED BY THE PRINCIPLES OF EQUITY AND ACCESSIBILITY FOR ALL COMMUNITIES AND WILL INCLUDE THE INPUT OF UNDERSERVED STAKEHOLDERS. OUR 5-YEAR GOALS ARE TO (I) SOLICIT OVER 500 APPLICATIONS AND LAUNCH 45 PROJECTS, WHERE AT LEAST 15 HAVE 1 WOMAN OR URM INNOVATOR ON THE TEAM, AND (II) BLAZE A TRAIL TO ALLEVIATE SUFFERING FROM NEUROLOGICAL CONDITIONS FOR ALL, INCLUDING THE UNDERSERVED...THE EQUITECH WAY.

ONE COMMUNITY

BIOMARKERS OF COGNITIVE DECLINE AMONG NORMAL INDIVIDUALS: THE BIOCARD COHORT

THE PURPOSE OF THIS MODIFICATION IS TO PROVIDE INCREMENTAL FUNIDNG OF $2,622,000.00 INTO THE INSTRUMENT TO COVER COSTS FOR MALARIA INITIATIVE UNDER P

THE MALAWI CLINICAL TRIALS UNIT

MULTICENTER AIDS COHORT STUDY- PART B (BALTIMORE SITE)

BEING NEW CA IN THE AMOUNT OF $45 000 000 TO PROVIDE SUPPORT FOR THE PROGRAM 'TANZANIA CAPACITY AND COMMUNICATION PROJECT. THE AMOUNT OBLIGATION IS $

INCREASE COVERAGE AND USE OF KEY LIFE SAVING MALARIA INTERVENTIONS IN SUPPORT OF THE UGANDA NATIONAL MALARIA STRATEGY AND THE NATIONAL MALARIA CONTRO

THE MALAWI CLINICAL TRIALS UNIT

SPORE IN CERVICAL CANCER

UNIV. TECHNICAL ASSISTANCE PROJECTS IN SUPPORT OF THE GLOBAL AIDS PROGRAM

NEW HORIZONS IN THE PREVENTION AND TREATMENT OF FOOD ALLERGY - LEADERSHIP CENTER SUMMARY/ABSTRACT FOOD ALLERGY RESEARCH HAS INCREASED DRAMATICALLY OVER THE PAST 20 YEARS, IN LARGE PART TO THE EFFORTS OF COFAR. NEW APPROACHES FOR BOTH TREATMENT AND PREVENTION HAVE BEEN INTRODUCED, AS HAVE THE UNDERSTANDING OF THE IMMUNOLOGIC BASIS OF FOOD ALLERGY. THE OVERARCHING GOAL OF THE RESEARCH AGENDA PROPOSED IN THIS APPLICATION IS TO MAINTAIN COFAR'S POSITION AS AN INTERNATIONAL LEADER IN THE STUDY OF FOOD ALLERGY, INCLUDING OPTIMAL CHARACTERIZATION OF THE DISEASE AND DEVELOPMENT OF THE NEXT GENERATION OF TREATMENTS AD PREVENTION. THE RESEARCH AGENDA WILL BE BASED FIRST AND FOREMOST ON THE BEST POSSIBLE SCIENCE, BUT TO MAXIMIZE PRODUCTIVITY WE WILL ALSO NEED TO PLAN JUDICIOUSLY SO THAT ALL AVAILABLE RESOURCES CAN BE USED TO THEIR UTMOST CAPACITY. THEREFORE, THE RESEARCH AGENDA WILL NEED TO CAREFULLY SELECT AND STAGE PROTOCOLS BASED NOT JUST ON THEIR POTENTIAL TO ADVANCE THE FIELD, BUT ALSO WITH CAREFUL CONSIDERATION REGARDING OTHER NOVEL TREATMENTS THAT MAY BE UNDER DEVELOPMENT, AND HOW ONE STUDY MAY INFORM THE NEXT. FINALLY, THE OVERALL RESEARCH STRATEGY WILL NEED TO WORK IN UNISON WITH THE NIAID, THE SACCC AND EACH CRC IN THE CONSORTIUM. THIS OVERALL AGENDA WILL BE ACCOMPLISHED THROUGH THE FOLLOWING MAJOR COMPONENTS: 1) TO IMPLEMENT A LEADERSHIP TEAM CAPABLE OF PROVIDING OPTIMAL ADMINISTRATION OF THE CONSORTIUM, INCLUDING FINANCIAL, OPERATIONAL, AND MANAGERIAL ASPECTS, AS WELL AS PROTOCOL DEVELOPMENT AND IMPLEMENTATION, DATA COLLECTION AND ANALYSIS, AND PUBLICATIONS AND PRESENTATIONS, WITH JUDICIOUS FINANCIAL MANAGEMENT. DR. ROBERT WOOD WILL LEAD THIS TEAM, WITH CO-PIS DRS. SCOTT SICHERER AND SUPINDA BUNYAVANICH. THE TEAM WILL INCLUDE EXPERTS IN CLINICAL TRIALS AS WELL AS THE LABORATORY STUDY OF FOOD ALLERGY. THE TEAM WILL ALSO INCLUDE A FINANCIAL ADMINISTRATOR AS WELL AS A HIGHLY EXPERIENCED GRANTS MANAGEMENT GROUP AT JOHNS HOPKINS. THE LEADERSHIP TEAM WILL WORK CLOSELY WITH THE NIAID AND SACCC, TOGETHER PROVIDING DAY-TO-DAY MANAGEMENT OF ALL CLINICAL OPERATIONS WITHIN THE CONSORTIUM. 2) TO DEVELOP THE NECESSARY COMMITTEE STRUCTURE TO GUIDE AND IMPLEMENT THE CONSORTIUM'S ADMINISTRATIVE AND CLINICAL OPERATIONS. 3) TO DEVELOP A STRUCTURE OF FINANCIAL MANAGEMENT THAT WILL MAKE OPTIMAL USE OF ALL COFAR FUNDS AND RESOURCES. 4) TO INTEGRATE THE BIOMARKER FACILITY INTO EACH CLINICAL PROTOCOL. IT IS ANTICIPATED THAT A MINIMUM OF 2 MAJOR PROTOCOLS, INCLUDING BOTH CLINICAL TRIALS AND NON-INTERVENTIONAL STUDIES, WILL BE INITIATED AND COMPLETED OVER THE SEVEN-YEAR FUNDING PERIOD, AND THIS COULD RISE TO 4 OR EVEN 5 PROTOCOLS DEPENDING ON THE SIZE, DURATION, AND COMPLEXITY OF EACH STUDY. IF SUCCESSFUL, THIS RESEARCH AGENDA WILL DEFINE NOT JUST THE NEXT 7 YEARS OF COFAR, BUT WILL ALSO ESTABLISH THE PLATFORM FOR THE NEXT DECADE(S) OF FOOD ALLERGY RESEARCH.

PURPOSE: THE PURPOSE OF THIS COOPERATIVE AGREEMENT TO PROVIDE UNDERGRADUATE/GRADUATE RESEARCHERS, INDIVIDUALS WITH BACHELORS OR MASTER'S DEGREES, POST-DOCTORAL ASSOCIATES, SENIOR RESEARCH FELLOWS AND ACADEMIC AFFILIATES WITH FELLOWSHIP OPPORTUNITIES AND FINANCIAL ASSISTANCE TO OBTAIN LABORATORY EXPERIENCES AND AID IN DEVELOPING COLLABORATIVE RESEARCH RELATIONSHIPS WITH NIST STAFF WITHIN THE NIST BOULDER LABORATORY.ACTIVITIES TO BE PERFORMED: PREP SEEKS TO ENCOURAGE THE GROWTH AND PROGRESS OF SCIENCE AND ENGINEERING IN THE UNITED STATES, INCLUDING THE ENCOURAGEMENT OF WOMEN AND MINORITY RESEARCHERS SEEKING TO FURTHER THEIR PROFESSIONAL DEVELOPMENT, AND TO NURTURE RESEARCHERS AND POST-DOCTORAL ASSOCIATES CONSIDERED TO BE POTENTIAL FUTURE NIST EMPLOYEES.EXPECTED OUTCOMES: THE OBJECTIVES OF THE PREP PROGRAM ARE TO: 1) ENCOURAGE THE GROWTH AND PROGRESS OF SCIENCE AND ENGINEERING IN THE UNITED STATES BY PROVIDING RESEARCH OPPORTUNITIES FOR PREP RESEARCHERS WITH NIST SCIENTISTS AND ENGINEERS AND EXPOSING THEM TO CUTTING-EDGE RESEARCH AND DEVELOPMENT (R&D); 2) PROMOTE THE PURSUIT OF DEGREES OR PROFESSIONAL DEVELOPMENT, AS APPLICABLE, FOR PREP RESEARCHERS; AND 3) PROMOTE DIVERSITY AND EQUITY IN STEM.INTENDED BENEFICIARIES: NIST AND NIST RESEARCHERS, AND UNDERGRADUATE/GRADUATE RESEARCHERS, INDIVIDUALS WITH BACHELORS OR MASTER'S DEGREES, POST-DOCTORAL ASSOCIATES, SENIOR RESEARCH FELLOWS AND ACADEMIC AFFILIATES, EMPLOYED BY OR AFFILIATED WITH THE UNIVERSITIES.SUBRECIPIENT ACTIVITIES: THE RECIPIENT DOES INTEND TO SUBAWARD FUNDS.

THIS FIVE-YEAR COOPERATIVE AGREEMENT WILL ALLOW USAID/INDIA TO SUPPORT THE GOVERNMENT OF INDIA¿S GOAL OF AN AIDS-FREE GENERATION, THIS ACTIVITY WILL RAPIDLY DEMONSTRATE AND ASSESS NEW MODELS TO INCREASE ACCESSIBILITY, AVAILABILITY, AND DEMAND OF HIGH QUALITY, COMPREHENSIVE HIV PREVENTION, CARE AND TREATMENT SERVICES; WHILE STRENGTHENING SYSTEMS AND THE ENABLING ENVIRONMENT FOR KPS, ESPECIALLY HARD-TO-REACH KPS, THEIR PARTNERS, SPOUSES AND CHILDREN TO HAVE EQUITABLE ACCESS TO HIV/AIDS AND SOCIAL SERVICES.

THE SBC ACTIVITY SEEKS TO TRANSFORM HOUSEHOLDS, COMMUNITIES AND SYSTEMS FOR IMPROVED HEALTH AND DEVELOPMENT OUTCOMES THROUGH SOCIAL AND BEHAVIOR CHANGE. IT WILL CONTRIBUTE TO THE ACHIEVEMENT OF HEALTH AND DEVELOPMENT OUTCOMES THROUGH IMPROVED ADOPTION OF HEALTH BEHAVIORS (E.G. INCREASED, CONSISTENT, AND CORRECT USE OF MOSQUITO NETS; INCREASED ADHERENCE TO ARVS) AT INDIVIDUAL, HOUSEHOLD, AND COMMUNITY LEVELS. THIS ACTIVITY WILL WORK WITH THE GOU, IMPLEMENTING PARTNERS AND STAKEHOLDERS TO IMPLEMENT AND SCALE UP QUALITY SBC INTERVENTIONS THAT DIRECTLY AFFECT THE INTERNAL, STRUCTURAL AND SOCIAL FACTORS IN ORDER TO INCREASE ADOPTION OF IMPROVED HEALTH BEHAVIORS AND ULTIMATELY IMPACT HEALTH AND DEVELOPMENT OUTCOMES. THE ACTIVITY WILL ACCOMPLISH RESULTS THROUGH FOUR INTERMEDIATE RESULTS:

COGNITION AND HIPPOCAMPAL/CORTICAL SYSTEMS IN AGING

KNOWLEDGE FOR HEALTH

JOHNS HOPKINS-TUFTS TRIAL INNOVATION CENTER

DATA ANALYSIS AND COORDINATION CENTER FOR THE MACS-WIHS COMBINED COHORT STUDY

PEDIATRIC ADOLESCENT VIRUS ELIMINATION (PAVE) MARTIN DELANEY COLLABORATORY - ABSTRACT THE IMMEDIATE ESTABLISHMENT OF THE LATENT HIV-1 RESERVOIR IN RESTING MEMORY CD4+ T CELLS PRECLUDES HIV-1 CURE, COMPELLING ART FOR A LIFETIME IN CHILDREN. THE MISSION OF THE PAVE COLLABORATORY IS TO USE CUTTING-EDGE SCIENCE TO ESTABLISH A DEEP AND BROAD UNDERSTANDING OF THE IMMUNOPATHOGENESIS OF PEDIATRIC HIV-1 RESERVOIRS, ACROSS THE AGE SPECTRUM, AND TO DEMONSTRATE PRECLINICAL SAFETY AND EFFICACY OF NOVEL THERAPEUTICS TO ERADICATE RESERVOIRS AND CONTROL REBOUND THAT WILL PAVE THE WAY FOR FUTURE INTERVENTIONAL HUMAN STUDIES TOWARD A LIFETIME OF SUSTAINED HIV-1 CONTROL OFF ART. WE HYPOTHESIZE THAT THE UNIQUE FEATURES OF THE INFANT IMMUNE SYSTEM AT THE TIME OF RESERVOIR ESTABLISHMENT IMPACT THE CHARACTERISTICS OF LONG-TERM VIRUS PERSISTENCE, SUSCEPTIBILITY TO IMMUNE- MEDIATED CLEARANCE, AND REACTIVATION THAT ARE DISTINCT FROM ADULT INFECTIONS, WARRANTING IN-DEPTH INVESTIGATION TO INFORM CURE THERAPEUTICS SUITABLE FOR CHILDREN. WE WILL TEST THIS HYPOTHESIS AND EXECUTE THE PAVE SCIENTIFIC AGENDA THROUGH ACCOMPLISHMENT OF THE FOLLOWING SPECIFIC AIMS: 1. DEFINE THE ESTABLISHMENT AND EVOLUTION OF THE HIV LATENT RESERVOIR IN PERINATAL INFECTION. 2. ENHANCE PEDIATRIC IMMUNITY AND BROADLY NEUTRALIZING ANTIBODY (BNAB) DELIVERY TO ACHIEVE POST-TREATMENT CONTROL OF HIV-1 OFF ART. 3. DEPLOY IMMUNE-TARGETED STRATEGIES TO ELIMINATE VIRUS RESERVOIRS. 4. OPTIMIZE VIROLOGIC, IMMUNOLOGIC, AND IMAGING METHODS TO ASSESS EFFICACY OF HIV-1/S(H)IV CURE INTERVENTIONS. 5. FOSTER COMMUNITY ENGAGEMENT IN PEDIATRIC HIV CURE RESEARCH. THE PAVE PROGRAM IS MULTIDISCIPLINARY, MULTICULTURAL, AND ITERATIVE WITH A NIMBLE STRUCTURE ENCOMPASSED BY FOUR HIGHLY SYNERGISTIC RESEARCH FOCI AND A DOMESTIC AND INTERNATIONAL COMMUNITY PROGRAM THAT WILL RAPIDLY INCORPORATE NEW SCIENTIFIC DIRECTIONS AND FEEDBACK FROM OUR STAKEHOLDERS. THE PAVE LEADERSHIP TEAM SPANS DIVERSE SCIENTIFIC EXPERTISE AND EXHIBITS ADDITIONAL DIVERSITY IN TERMS OF GENDER, ACADEMIC RANK, AND COUNTRY OF ORIGIN. EACH OF THE RESEARCH FOCI ALSO INCLUDES JUNIOR FACULTY CO-INVESTIGATORS TO FACILITATE THEIR CAREER DEVELOPMENT WITHIN THE HIV-1 RESEARCH SPACE. THROUGH THE COLLECTIVE EFFORTS OF OUR SCIENTIFIC LEADERSHIP, EXECUTIVE COMMITTEE, SCIENTIFIC ADVISORY BOARD, INVESTIGATORS, INDUSTRY PARTNERS, NETWORK COLLABORATIONS, AND DOMESTIC AND INTERNATIONAL COMMUNITY PROGRAM, PAVE ANTICIPATES MEETING THE FOLLOWING OVERALL MILESTONES OF: 1) UNDERSTANDING EARLY LIFE IMMUNITY AND EARLY ANTIRETROVIRAL TREATMENT ON THE COMPOSITION AND STABILITY OF THE LATENT RESERVOIR, INCLUDING IN NAÏVE T CELLS, AND POTENTIAL FOR HIV-1 REMISSION; 2) ELIMINATING OF THESE RESERVOIRS IN PRE-CLINICAL STUDIES OF IMMUNE-TARGETED STRATEGIES; 3) DEFINING THE ROLE OF MYELOID CELLS IN HIV-1 PERSISTENCE AND REBOUND, INCLUDING IN THE CNS; 4) ESTABLISHING NOVEL APPROACHES TO ENHANCE PEDIATRIC IMMUNITY THROUGH ACTIVE AND PASSIVE IMMUNIZATION; 5) DEVELOPING CUTTING-EDGE APPROACHES TO QUANTIFY AND MONITOR PROVIRAL RESERVOIRS TO MEASURE CLINICAL TRIAL EFFICACY, AND 6) PROMOTING ACTIVE COMMUNITY ENGAGEMENT IN PEDIATRIC HIV-1 CURE RESEARCH. THESE MILESTONES WILL HELP ACHIEVE THE VISION OF SUSTAINED ART-FREE CONTROL OF HIV-1 REPLICATION IN PEDIATRIC POPULATIONS.

SOCIAL BEHAVIOR CHANGE COMMUNICATIONS/SOCIAL MARKETING (SBCC/SM)

ADDRESSING UNMET NEED IN HIV TESTING SERVICES (HTS) THROUGH EFFECTIVE DELIVERY MODELS IN MALAWI UNDER PEPFAR

THE MAJOR EXTREMITY TRAUMA RESEARCH CONSORTIUM

JOHNS HOPKINS AIDS CLINICAL TRIALS UNIT

MAKERERE UNIV.-JOHNS HOPKINS UNIV. HIV CLINICAL TRIALS UNIT-KAMPALA, UGANDA

CLINICAL RESEARCH SITES FOR THE MACS/WIHS COMBINED COHORT STUDY (MACS/WIHS-CCS) - BALTIMORE/WASH DC CENTER

INVESTING IN INNOVATION -- VALIDATION GRANTS

LEADER WITH ASSOCIATES COOPERATIVE AGREEMENT

CENTER FOR POINT-OF-CARE TECHNOLOGIES RESEARCH FOR SEXUALLY TRANSMITTED DISEASES